LUXEMBOURG / Jul 30, 2024 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its Second Quarter 2024 financial results.
Earnings Release
Wednesday, August 21, 2024
Time: After Market Close
Conference Call
Wednesday, August 21, 2024
Time: 5:00 p.m. ET
Quiet Period
Friday, August 2 through Wednesday, August 21, 2024
To participate, please dial
+1 888 596 4144 (Toll-Free)
+1 646 968 2525 (International)
Entry Passcode: 3884034
Webcast: click here
About Auna
Auna is a Latin American healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish Speaking Americas. Founded in 1989, Auna has built one of Latin America’s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of March 31, 2024, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.2 million healthcare plans.
For more information visit www.aunainvestors.com
| Last Trade: | US$4.83 |
| Daily Change: | -0.09 -1.83 |
| Daily Volume: | 76,831 |
| Market Cap: | US$144.900M |
November 20, 2025 November 20, 2025 September 24, 2025 August 19, 2025 May 20, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load